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https://doi.org/10.1016/j.ccell.2018.03.013SUMMARYTransmissible cancers are clonal lineages that spread through populations via contagious cancer cells.
Although rare in nature, two facial tumor clones affect Tasmanian devils. Here we perform comparative ge-
netic and functional characterization of these lineages. The two cancers have similar patterns ofmutation and
show no evidence of exposure to exogenous mutagens or viruses. Genes encoding PDGF receptors have
copy number gains and are present on extrachromosomal double minutes. Drug screening indicates caus-
ative roles for receptor tyrosine kinases and sensitivity to inhibitors of DNA repair. Y chromosome loss
from amale clone infecting a female host suggests immunoediting. These results imply that Tasmanian devils
may have inherent susceptibility to transmissible cancers and present a suite of therapeutic compounds for
use in conservation.INTRODUCTION
Tasmanian devils (Sarcophilus harrisii) are marsupial carnivores
endemic to the Australian island of Tasmania. This species is
considered endangered due to the emergence of a clonally
transmissible cancer known as devil facial tumor 1 (DFT1)
(Pearse and Swift, 2006). DFT1 presents as facial and oral tu-
mors, and the disease is contagious between animals by the
transfer of living cancer cells by biting (Hamede et al., 2013;Significance
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in 1996, DFT1 is a somatic clone that originally arose from the
cells of an individual female devil (Deakin et al., 2012; Hawkins
et al., 2006; Murchison et al., 2012). The lineage spawned by
this animal has subsequently spread widely throughout Tasma-
nia, causing significant declines in devil populations (Hawkins
et al., 2006; Lazenby et al., 2018).
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cancer, DFT2, causes oral and facial tumors that are grossly
indistinguishable from those caused by DFT1 (Pye et al.,
2016b). However, DFT2 tumors are histologically, cytogeneti-
cally, and genetically distinct from DFT1. Indeed, karyotype evi-
dence suggests that DFT2 arose from the somatic cells of a male
animal, in contrast to the female origin of DFT1 (Pye et al.,
2016b). To date, DFT2 has been confirmed in only 11 devils, all
located on the Channel Peninsula in Tasmania’s south-east
(Kwon et al., 2018).
The discovery of a second transmissible cancer in Tasmanian
devils was entirely unexpected and remains unexplained. Other
than DFT1 and DFT2 in devils, only one other naturally occurring
transmissible cancer is known in mammals, which is the
11,000-year-old canine transmissible venereal tumor in dogs
(Murchison et al., 2014). Outside of mammals, only five transmis-
sible cancers have been observed, all of which cause leukemia-
like diseases in marine bivalves (Metzger et al., 2015, 2016). The
scarcity of known transmissible cancers in nature suggests that
such diseases emerge rarely. Furthermore, in Tasmanian devils,
there were no reports of animals with facial tumors comparable
with those caused by DFT1 and DFT2 prior to 1996 (Hawkins
et al., 2006; Loh et al., 2006a). Thus, the recent identification of
two transmissible cancers in Tasmanian devils, detected within
an interval of 18 years, is very surprising, and suggests that
exogenous or anthropogenic factors may contribute to risk of
transmissible cancer development specifically in this species.
Despite an urgent need to further understand the molecular
basis of transmissible cancers in Tasmanian devils, little is
known of the underlying genetic changes that initially caused
these cancers and that promote their colonization of allogeneic
hosts. The genome of DFT1 indicates that this lineage has ac-
quired several thousand mutations during its evolution (Murchi-
son et al., 2012). Although some genes have been somatically
altered (Miller et al., 2011; Murchison et al., 2012; Taylor et al.,
2017), no ‘‘driver’’ mutations with a clear causative role in
DFT1 emergence or evolution have been identified. Major histo-
compatibility complex (MHC) molecules are undetectable on the
surface of most DFT1 cells, likely explaining the low immunoge-
nicity of these cells in allogeneic hosts (Siddle et al., 2013). How-
ever, no mutations in genes involved in antigen presentation
have been defined. DFT2 has not yet been characterized beyond
a preliminary assessment of its histology, karyotype, and genetic
profiles at microsatellite and MHC loci (Pye et al., 2016b).
Given the similar phenotypes of DFT1 and DFT2, the emer-
gence of DFT2 provides an opportunity to understand the com-
mon factors that underlie transmissible cancers in Tasmanian
devils. Here, we provide a comparative genetic and functional
characterization of DFT1 and DFT2, analyzed alongside 46
normal devil genomes.
RESULTS
Tissues-of-Origin
DFT2 tumors are histologically distinct from those of DFT1 (Pye
et al., 2016b). DFT2 is characterized by sheets of pleomorphic
cells (amorphic to stellate and fusiform), whereas DFT1 is
composed of pleomorphic round cells often arranged in bundles,
cords, or packets (Loh et al., 2006a; Pye et al., 2016b). DFT1 ex-
presses neuroectodermal markers, and is proposed to be of608 Cancer Cell 33, 607–619, April 9, 2018Schwann cell origin; indeed, a Schwann cell marker, PRX, is
used to confirm DFT1 diagnosis (Loh et al., 2006b; Murchison
et al., 2010; Tovar et al., 2011). DFT2 does not express PRX
(Pye et al., 2016b) and its histogenesis remains unknown.
We used a panel of antibodies to broadly characterize the
DFT2 tissue-of-origin by immunohistochemistry. Similar to
DFT1, DFT2 is negative for cytokeratin and smooth muscle actin,
and positive for vimentin, neural-specific enolase, and S100 (Fig-
ure S1). The similarity in tissue markers and gross phenotype be-
tween DFT1 and DFT2 suggests that these cancers arose from a
similar cell type.
Germline Genotypes and Populations-of-Origin
To further understand the identities, locations and relationship
between the DFT1 and DFT2 founder individuals, whose cells
spawned the two lineages, we compared the germline alleles
present in DFT1 and DFT2 with those in the devil population.
Tasmanian devil genetic analysis has revealed population sub-
structure between eastern devil populations and those in the
more isolated north-west (Br€uniche-Olsen et al., 2014; Jones
et al., 2004; Miller et al., 2011). Genotyping of DFT1 and DFT2
(Table S1) at 320 nuclear polymorphic loci, and comparison
with 401 devils sampled from seven locations between 1999
and 2014 (Br€uniche-Olsen et al., 2016), confirmed that both
DFT1 and DFT2 arose from individuals with ‘‘eastern’’ genotypes
(Figure 1). Further analysis indicated that DFT1 clustered most
strongly with individuals sampled in north-east Tasmania (Mount
William) in 2004, whereas DFT2 bore closest identity with individ-
uals collected in 2014 from the Channel Peninsula (Figure 1).
Overall, these findings are consistent with the notion that DFT1
and DFT2 arose within the areas in which they were first
observed (Figure 1B), implying that both lineages may have
been discovered relatively soon after their emergence.
The independent emergence of transmissible cancers from
two Tasmanian devils both belonging to the eastern subpopula-
tion suggests the possibility of inherited germline predisposition
alleles that increase risk of transmissible cancer development.
We investigated this hypothesis by sequencing the genomes of
DFT1 and DFT2 (Table S1) and identifying and annotating their
founder individuals’ inherited germline single-nucleotide variant
(SNV) and small insertion and deletion (indel) alleles (variants
were considered likely to be germline if they were shared
with R1 normal devil or if they were found in both DFT1 and
DFT2, see the STAR Methods). Although a subset of these
caused putative non-synonymous gene alterations in 908 genes
(Table S1), none bore homology to known inherited cancer risk
loci in humans (Forbes et al., 2015). Overall, although this
approach revealed a number of candidate loci, we cannot
confirm their involvement in DFT risk.
Virus Screen
We next investigated the possibility that exposure to exogenous
pathogens, such as viruses, may increase the risk of DFT dis-
eases developing in Tasmanian devils.We produced de novo as-
semblies of two DFT1 and two DFT2 genomes, and used whole
genome and short read alignments to identify contigs that were
exclusive to tumors and absent from four normal devils (see
STAR Methods). This approach did not provide evidence for
exogenous viral DNA in DFT1 or DFT2 (Table S1), consistent
Figure 1. Origins of DFT1 and DFT2
(A) Map of Tasmania illustrating sampling locations of 400 devil individuals represented in (B). Number of individuals sampled from each location is labeled
(Br€uniche-Olsen et al., 2016). ‘‘East’’ and ‘‘West’’ denote the populations that cluster separately in (B), separated by dotted line. One individual was sampled from
a captive population and is not shown on map. Devil silhouettes depict locations and year of first observations of DFT1 and DFT2.
(B) Hierarchical clustering of 320 SNP genotypes across a panel of 401 devils, DFT1 (blue) and DFT2 (red); individuals are represented as rows and loci as
columns. Genotypes are coded as white (homozygous 1/1), black (homozygous 2/2), and gray (heterozygous 1/2). East and West populations, as defined in (A),
are labeled. Right, detail of Euclidian distance dendrogram with sampling years and locations of devils neighboring DFT1 and DFT2 genotypes.
See also Table S1 and Figure S1.with the results of previous screens for viruses in DFT1 using
sequence alignments and transmission electron microscopy
(Murchison et al., 2012; Pyecroft et al., 2007). However, we
cannot exclude the potential involvement of DNA viruses that
have not been maintained, small circular unintegrated DNA vi-
ruses not captured by our DNA extraction method, RNA viruses,
or other pathogens in triggering DFT emergence.
Mutational Signatures
Further evidence for the involvement of exogenous agents in
DFT1 and DFT2 pathogenesis might be gained from examination
of mutational signatures (Alexandrov et al., 2013, 2015a; Baez-
Ortega and Gori, 2017). The similarity in mutational spectra, a
representation of the six SNV mutation types together with their
immediate 50 and 30 contexts found in DFT1 and DFT2 tumors,
suggests that similar mutational processes have operated in
these two cancers (Figure 2A). We applied Markov Chain Monte
Carlo sampling with a Bayesian statistical model to refit the
30mutational signatures cataloged in human cancers (COSMIC,
2017) to pools of mutations in DFT1 and DFT2. This analysis re-
vealed that refitting with human mutational signatures 1 and 5,
both of which are ‘‘clock-like’’ age-associated signatures, which
are almost universally active in human cancer and normal cells
and are not indicative of exogenous mutational exposures (Alex-
androv et al., 2013, 2015a; Blokzijl et al., 2016; Ju et al., 2017;
Rahbari et al., 2016), adequately reconstructed the mutational
spectra observed in both DFT1 and DFT2 (cosine similarity
0.93 and 0.95, respectively) (Figure 2B; Table S2).
Interestingly, neither DFT1 nor DFT2 genomes analyzed here
bear imprints of exposure to UV light, a mutagen that leaves a
readily recognizable mutational signature (Table S2). This con-
trasts with the transmissible venereal tumor in dogs, in which
40% of mutations have been caused by UV (Murchison et al.,
2014). Given that both DFT1 and DFT2 tumors are frequently
located on external regions of the face, this observation sug-
gests that either the nocturnal Tasmanian devil is rarely exposed
to UV or, alternatively, that the cells that propagate DFT1 andDFT2 are not those on the surface of cutaneous tumors, but
rather derive from non-exposed regions, such as the oral cavity
or deep within the tumor mass.
Early Somatic Mutations
Our analysis has not provided evidence that exogenous expo-
sures or germline risk contributed to DFT emergence. Next, we
further characterized the functional consequences of putative
somatic mutations in the two cancers. We identified 2,884
SNVs and 410 indels (DFT1), and 3,591 SNVs and 572 indels
(DFT2), which were present in the genomes of two sequenced
DFT1 tumors (86T and 88T, collected from Central Tasmania
in 2005 and Eastern Tasmania in 2007, respectively) or two
sequenced DFT2 tumors (202T2 and 203T3, both collected
from the Channel Peninsula in 2014), but were not detected in
the genomes of 46 normal devils (Figure 2C; Table S2). As we
do not have germline DNA from the DFT1 or DFT2 founder devils,
we cannot ascertain the provenance of these variants; however,
a subset will be early somatic variants that occurred after emer-
gence of each lineage and prior to divergence of the tumor iso-
lates analyzed here (Figure 2C). Only 18 (18 SNVs, 0 indels) of
these variants in DFT1 and 19 (16 SNVs, 3 indels) in DFT2 were
predicted to be non-synonymous, with no intersection between
the genes harboring non-synonymous variants in DFT1 and
DFT2 (Figure 2C; Table S2). None of these putative early somatic
non-synonymous SNV or indel mutations occurred in a set of
genes with confirmed causative involvement in human cancer
(http://cancer.sanger.ac.uk/cosmic/census/) (Tables S2 and
S3). Themajority of thesemutationswere predicted to be hetero-
zygous (Table S2). However, we observed that DFT1 harbored a
hemizygous nonsense mutation inWWC3 (R945* in exon 21/24),
and DFT2 carried a hemizygous truncating indel inMPDZ (S496X
in exon 9/47); in both cases, the second copy was deleted, likely
leading to complete loss-of-function (Tables S2 and S4). We
genotyped these variants across eight additional geographically
dispersed DFT1 tumors (WWC3) and two additional DFT2 tu-
mors (MPDZ) (Table S2); in both cases, the relevant variantCancer Cell 33, 607–619, April 9, 2018 609
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Figure 2. Single-Nucleotide Variants and In-
dels in DFT1 and DFT2
(A) Mutational spectra of single-nucleotide variants
(SNVs). Only SNVs that are unique to one tumor
within a lineage, and therefore likely to be somatic,
are displayed (n = 6,812 [DFT1], n = 626 [DFT2]).
Each bar represents a mutation category defined by
themutation type shown in upper gray panel, and its
immediate 50 and 30 base context; mutation classes
are presented in the order shown in (COSMIC,
2017), and prominent mutation types are labeled (N,
any base). Mutation counts are normalized to cor-
responding nucleotide triplet frequencies in the devil
genome.
(B) Best fit of two mutational signatures. Signatures
1 and 5, extracted from human cancers (Alexandrov
et al., 2013), were fitted to SNVs derived from DFT1
and DFT2. DFT1 and DFT2 SNVs were represented
by a pool of those that are unique to one tumor
within each lineage. Error bars display 95%
Bayesian credible intervals of the posterior proba-
bility after 105 Markov Chain Monte Carlo samples.
(C) Analysis of early somatic variants. Left, simplified
phylogenetic trees represent origins of DFT1 and
DFT2 from their respective founder devils, and their
respective divergence after the most recent com-
mon ancestor (MRCA) of the tumor isolates analyzed here (86T and 88T, DFT1) and (202T2 and 203T3, DFT2). Plausible range of somatic SNV and indel counts
within the trunk of each tree is indicated, with the upper bound defined by those variants shared between both tumor isolates in each lineage but not detected in
46 normal devil genomes. The upper bounds of early somatic non-synonymous mutations in each lineage is shown and, right, annotation of these variants is
represented. * indicates the truncating mutations in WWC3 and MPDZ are hemizygous as in both cases the second allele has been deleted.
See also Tables S2, S3, and S4.was present in all tumors analyzed, suggesting that these vari-
ants may be somatic mutations acquired early, prior to clonal
diversification. Interestingly, both WWC3 and MPDZ are pro-
posed to encode negative regulators of YAP1 and WWTR1/
TAZ, core effectors of the Hippo signaling pathway, which has
conserved roles in development, regeneration, and cancer
(Han et al., 2017; Juan and Hong, 2016; Moroishi et al., 2015;
Varelas et al., 2010; Zanconato et al., 2016). YAP1 and
WWTR1/TAZ are transcriptional co-activators that shuttle be-
tween cytoplasm and nucleus; in both DFT1 and DFT2 cells,
YAP1 and WWTR1/TAZ are expressed and show nuclear locali-
zation, indicating activity (Figure S1). The Hippo pathway has
been implicated in several human cancer histotypes, and is of
particular importance in Schwann cell cancers (Wu et al., 2018;
Zanconato et al., 2016).
Cytogenetics and Structural Variants
Structural variants (SVs) are another source of somatic variation
that may have contributed to DFT oncogenesis. Chromosome
painting revealed that the DFT2 karyotype (Pye et al., 2016b)
appears to have arisen via insertion of chromosome 6 into the
pericentric region of chromosome 2, forming a large derived
chromosome (Figure 3A). We used discordantly mapped
paired-end sequence reads and PCR screens to identify putative
somatic SVs in DFT1 and DFT2. The pattern of SVs in DFT1 re-
vealed a cluster of rearrangements on chromosome 2 that was
acquired prior to divergence of the tumors sequenced in this
study (Figure 3B; Table S5). We also identified a focus of SVs
on chromosome 1 in one DFT1 tumor, which marks the region
from which the extrachromosomal double minutes (DMs) in
this tumor derive (Taylor et al., 2017) (Figures 3A and 3B;610 Cancer Cell 33, 607–619, April 9, 2018Table S5). We identified 64 and 23 rearrangements involving
genes in one or both DFT1 genomes or in one or both DFT2 ge-
nomes analyzed here, respectively, but not in 34 normal devil ge-
nomes (Table S5). These predicted three DFT1-specific in-frame
fusion genes, PDZD11-RFX2, CAMK2A-NEURL1B, and EZH2-
ETNK2; the latter two potential fusion genes were found in only
one of two analyzed DFT1 tumors, and are thus unlikely to
have arisen early in DFT1 tumor evolution (Tables S3 and S5).
Genotyping of PDZD11-RFX2, however, confirmed its presence
in eight additional geographically dispersed DFT1 tumors (Table
S2), suggesting that it may be a somatic rearrangement that
occurred early in the DFT1 lineage. EZH2, encoding a histone
methyltransferase, is dysregulated in many cancers (Kim and
Roberts, 2016), but it is unclear if the disruption of this gene in
a subset of DFT1s has provided a selective advantage to this
lineage (Table S3). Overall, the DFT2 genomes analyzed here
have simpler structures and fewer rearrangements than those
of the DFT1 genomes analyzed here. However, similar microho-
mology-mediated repair processes operated during clonal evo-
lution of both DFT1 and DFT2 (Figure 3B; Table S5).
Telomeres
Rearrangements in cancer are frequently triggered by telomere
crisis (Maciejowski and de Lange, 2017). Tasmanian devils have
unusual telomeres characterized by extreme length dimorphism
between homologs (Bender et al., 2012). This feature has been
lost in DFT1, which carries uniformly short telomeres (Bender
et al., 2012). We used fluorescence in situ hybridization (FISH) to
examine telomere length in DFT2. Our analysis revealed that cells
derived from DFT2 exhibited telomere length dimorphism be-
tween homologs similar to normal cells (Figure 3C), and indicated
Figure 3. Structural Variation and Telo-
meres in DFT1 and DFT2
(A) Chromosome painting. Normal devil female,
DFT1 (tumor 88T) and DFT2 (tumor 203T3) meta-
phases hybridized with devil chromosome-spe-
cific fluorescent probes. DM, double minutes; the
Y chromosome lacks a specific probe and is
indicated with ‘‘Y’’; * indicates locations of overlap
between chromosome arms that were present in
images used to generate karyotypes.
(B) Structural variant (SV) mutations. Larger upper
circos plots represent likely somatic SVs shared
between 86T and 88T (DFT1) or 202T2 and 203T3
(DFT2), respectively, but that are not found in 34
normal devils. Lower circos plots represent SVs
that are uniquely found in one of the sequenced
tumors of the two lineages. DM, SVs involved in
double minutes. Blue or red lines connect chro-
mosomal coordinates involved in SV. Stacked bar
plots indicate percentage of breakpoints display-
ing short regions of microhomology, non-tem-
plated sequence insertions or blunt ends. n.s.,
Pearson’s chi square test, p > 0.05.
(C) Telomeres. Normal devil female, DFT1 (tumor
88T) and DFT2 (tumor 202T2) metaphases hy-
bridized with telomere-specific fluorescent probes
(green). Chromosomes are labeled red. DMs and Y
chromosome are indicated, as well as site of
integration of chromosome 6 into the derivative
chromosome 2 in DFT2.
See also Tables S3 and S5.that it was the chromosome 6 homolog with short telomeres that
was incorporated into chromosome 2 to generate the large deriv-
ative chromosome in DFT2 (Figure 3C). Thus, although loss of
telomere length dimorphism is not essential for the emergence
of transmissible cancers in Tasmanian devils, this species’ un-
usual telomere organization may contribute to risk of chromo-
somal rearrangement, which may predispose to DFT cancer.
Copy Number Variants
We next characterized copy number variants (CNVs) in the two
cancers. A comparison of CNVs in DFT1 and DFT2 confirmed
that all of the tumor isolates analyzed here are largely diploid
(Figure 4A; Table S4). Most CNVs in DFT1 and DFT2 involved
different genomic regions; however, an 18.4 megabase hemi-
zygous deletion on chromosome 3 was found in both lineages
(Figure 4A; Table S4). This CNV, which was not detected in 46
normal devil genomes suggesting that it is possibly somatic (Fig-
ure S2), reduces dosage of 74 genes in both DFT1 and DFT2
(Figure 4B and Table S4). One gene in DFT1 (MAST3) (Murchison
et al., 2012) and four genes in DFT2, including HGF and TP73,
have undergone homozygous deletion (Figure 4B; Table S4);
the other two homozygously deleted genes in DFT2,CACNA2D1
and ENSSHAG0000005243, are linked to HGF and TP73,
respectively. Interestingly, TP73 acts downstream of Hippo
pathway effectors to activate apoptosis (Moroishi et al., 2015).
Copy number gains have increased the dosage of 1,129 genes
in DFT1 and 501 genes in DFT2. Strikingly, we observed that
genes encoding the two platelet-derived growth factor
receptors (PDGFRs), PDGFRA and PDGFRB, were respectively
gained in copy number in DFT2 (copy number 4, focal amplifica-
tion) and some DFT1s (as part of extrachromosomal DMs)(Figure 4C;TablesS3andS4). This correlatedwith strongexpres-
sion of both PDGFRs inDFT1 andDFT2 (Figure 4C). Interestingly,
both PDGFA and PDGFB, encoding ligands for PDGFRs, have
undergone copy number gains in DFT1 (and PDGFA is addition-
ally involved in a SV in DFT1 [Murchison et al., 2012; Tables S4
and S5]). Furthermore, ERBB3 showed copy number gains in
DFT1 and is expressed in DFT1 (Hayes et al., 2017; Taylor
et al., 2017), and a subset of DFT1s carried gains of NRG2, en-
coding an ERBB ligand (Figure 4B; Tables S3 and S4).
Immune Genes and Loss of Y Chromosome
DFT clones must escape the host immune system despite their
statusasallogeneicgrafts. Interestingly,B2M, encodingacompo-
nent of MHC class I, has undergone hemizygous deletion in DFT1
(Figure 4D). This copy number loss may have contributed to the
downregulation of MHC observed in DFT1, resulting in this line-
age’s low immunogenicity (Siddle et al., 2013). We also observed
thatDFT1carriedaheterozygous truncatingmutation inCD40, en-
coding an immune co-stimulatory molecule that may be ex-
pressed together with MHC class II by Schwann cells (Figures 2C
and 4B) (Duan et al., 2007; Meyer zu Ho¨rste et al., 2010).
DFT2 faces a further potential immunological challenge due to
its possession of the Y chromosome. This lineage arose in amale
devil and has, to date, usually been observed in males (of the 11
reported cases of DFT2, 9 involve a male host [Kwon et al.,
2018]). This apparent bias toward male hosts raises the possibil-
ity that females may be less susceptible to DFT2 due to immuno-
genicity of antigens derived from the Y chromosome. We inves-
tigated the stability of the Y chromosome in DFT2 by PCR
amplifying the Y-linked SRY locus in a panel of DFT tumors
and their male and female hosts (Figure 4E; Table S6). AsCancer Cell 33, 607–619, April 9, 2018 611
Figure 4. Copy Number Variation and Functional Annotation in DFT1 and DFT2
(A) DFT1 (tumor 88T) and DFT2 (tumor 202T2) autosomal copy number generated using read counts at 735,281 SNP loci. Each dot represents log2R, where
R = (read depth in tumor)/(read depth in 203H), at a single SNP. CN, copy number. Arrow, chromosomal origin of DMs; arrowheads, hemizygous deletion
identified in both DFT1 and DFT2.
(B) Illustration of gene alterations. In each Venn diagram, number of genes altered inR1 DFT1 tumors are shown in blue on the left, and number of genes altered in
R1 DFT2 tumors are shown in red on the right; numbers of genes that are similarly altered inR1 DFT1 andR1 DFT2 tumor are shown in pink in the center of each
diagram. Only autosomal genes are considered and ‘disrupted’ alleles include only predicted loss-of-function alterations. Genes-of-interest are written in text
beside diagrams. * indicates these genes are amplified on extrachromosomal DMs.
(legend continued on next page)
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expected, Y chromosome DNAwas not detected in DFT1, which
is derived from a female founder devil, regardless of the gender
of the host (Figure 4E). In DFT2, Y chromosome DNA was pre-
sent in DFT2 tumors in male hosts, as well as in one DFT2 tumor
in a female host, Devil 812 (Devil 812 also carried two DFT1 tu-
mors [Kwon et al., 2018]). However, the Y chromosome locus
could not be detected in the DFT2 tumor derived from the sec-
ond female host, Devil 637 (Figure 4E).
DFT1 and DFT2 Drug Screen
To gain further insight into the signaling pathwayswhich promote
DFT1 and DFT2 growth and survival, and to uncover potential
therapeutic vulnerabilities, we performed a high-throughput
in vitro drug sensitivity screen. Four DFT1 cell lines and two
DFT2 cell lines (Table S7) were treated with a 7-point titration
(1,000-fold concentration range) of 104 pre-clinical and clinical
compounds with activity against a wide range of molecular
targets (Figure 5A; Table S7) prior to cell viability quantification.
Hierarchical clustering based on half maximal inhibitory concen-
tration (IC50) values indicated that DFT1 and DFT2 are distin-
guishable from each other based on their drug sensitivity
(Figure 5B); however, the two cancers share a striking overall
similarity in drug response profile compared with several hun-
dred human cancer cell lines (Figures 5C–5F; Table S7 [Yang
et al., 2013]).
Both DFT1 and DFT2 are sensitive to a suite of inhibitors of re-
ceptor tyrosine kinases (RTKs) (Figure 5C). In particular, DFT1
cell lines are remarkably responsive to Afatinib, an inhibitor of
ERBB2 and EGFR (DFT1 cell lines top 0.4%–1.1% most sensi-
tive of 959 cell lines, geometric mean DFT1 IC50: 9.8 nM) (Fig-
ure 5C). This sensitivity is likely mediated by ERBB2 inhibition,
as DFT1 is resistant to Gefitinib and Erlotinib, agents that specif-
ically target EGFR (Table S7). Remarkably, DFT1 cell lines show
significantly greater sensitivity to Afatinib than a panel of ERBB2-
amplified human breast cancer cell lines (Figure 5E; geometric
mean DFT1 IC50: 9.8 nM, geometric mean ERBB2
+ Breast can-
cer cell lines IC50: 314.9 nM; p = 0.000516, Wilcoxon rank-sum
test). DFT2, on the other hand, is highly sensitive to Axitinib, a
compound with activity against PDGFR, KIT, and vascular endo-
thelial growth factor receptor (VEGFR) (DFT2 cell lines top 0.2%–
0.4%most sensitive of 854 cell lines, geometric meanDFT2 IC50:
5.0 nM) (Figure 5C). In addition, both DFT1 and DFT2 show
sensitivity to Dasatinib, a tyrosine kinase inhibitor whose targets
include PDGFR, ABL, SRC, ephrins, and KIT (geometric mean
DFT1 IC50: 7.5 nM; geometric mean DFT2 IC50: 6.4 nM) (Fig-
ure 5C). Both DFT1 and DFT2 are markedly sensitive to
CHEK1/CHEK2 inhibitor AZD7762, and poly-ADP ribose poly-
merase (PARP) inhibitors Talazoparib and Olaparib, suggesting
that DFT cancers are intolerant of DNA damage (Figure 5D;(C) Copy number and immunohistochemistry for PDGFRA and PDGFRB. Reads m
cn.MOPS (Klambauer et al., 2012); each dot represents log2R for a single bin, w
variants are represented by dashed gray lines connected by black lines. Genes a
PDGFRB are shown. Brown stain reports expression, counterstained with blue h
(D) Copy number at B2M locus. Copy number was determined and displayed as
(E) PCR amplification of the Y chromosome-linked SRY locus. DFT1 tumors (95T, 8
labeled in blue and red, respectively, and DFT1 hosts (95H, 88H, 812H, and 813H
upper panel shows SRY product and the lower panel shows positive control (RP
(Kwon et al., 2018). Red arrows highlight presence (812T1) or absence (637T1) o
See also Tables S3, S4, S5, S6, and Figure S2.Table S7), perhaps explaining the remarkable genomic stability
observed in DFT1 (Deakin et al., 2012; Murchison et al., 2012).
The response of DFT cell lines to Talazoparib was particularly
notable and is comparable with that of highly sensitive
human Ewing’s sarcoma cell lines (geometric mean DFT1 IC50:
33.1 nM, top 0.2%–2.0% of 922 cell lines, geometric mean
DFT2 IC50: 74.2 nM, top 0.7%–5.2% of 922 cell lines, geometric
mean Ewing’s IC50: 330.2 nM, top 0.3%–72.1% of 922 cell lines)
(Brenner et al., 2012; Garnett et al., 2012) (Figure 5F). This sensi-
tivity likely does not reflect defects in homologous recombina-
tion, aswe do not detect evidence for COSMICmutational signa-
ture 3 (Figure 2A; Table S2) (Alexandrov et al., 2015b; Alexandrov
et al., 2013; COSMIC, 2017; Nik-Zainal et al., 2012; Nik-Zainal
et al., 2016). Altogether, this screen highlights key vulnerabilities
inherent to DFT cells and strongly implicates RTK signaling in
driving oncogenesis of both DFT1 and DFT2.
DISCUSSION
DFT2 has changed our perception of the nature of transmissible
cancers. Previously, transmissible cancers were believed to
arise very rarely in nature, with the existing examples represent-
ing exceptional cases that had overcome strong natural barriers.
Indeed, the observation that all sampled transmissible venereal
tumors in dogs belong to a single clone which originated several
thousand years ago (Murgia et al., 2006; Rebbeck et al., 2009;
Strakova et al., 2016) suggests that such canine cancers appear
and disperse infrequently. However, the emergence of DFT2,
together with the discovery of several transmissible cancers in
marine bivalves (Metzger et al., 2015, 2016), suggests that
some speciesmay have a particular vulnerability for the develop-
ment of this type of disease and that, at least in these species,
transmissible cancers may be spawned relatively frequently.
The reason for Tasmanian devils’ apparent susceptibility to
transmissible cancers is not clear. The striking similarities in tis-
sues-of-origin, genome architectures, mutational processes,
driver gene candidates, and drug vulnerabilities, strongly sug-
gest that DFT1 and DFT2 belong to the same cancer type and
arose via similar oncogenic mechanisms. DFTs are likely of neu-
roectodermal origin, and may show differentiation toward the
neural crest-derived Schwann cell lineage (Murchison et al.,
2010). The closest human cancer histotype to DFT is not clear
(Loh et al., 2006b), and comparative studies with human and vet-
erinary cancers are further hampered by lack of knowledge of the
body site from which DFT cancers first arise. It is notable that,
although Tasmanian devils are reported to have high frequencies
of host-derived neoplasia (Griner, 1979), no lesions have been
described that are consistent with pre-transmissible DFT; given
that hundreds of wild and captive devils are routinely monitoredapping within 500 base pair genomic bins were counted and normalized using
here R = (read count tumor)/(read count 203H). CN, copy number. Structural
re represented as black bars, and locations and orientations of PDGFRA and
ematoxylin. Scale bar, 30 mm.
in (C). Bins within B2M are colored in black. CN, copy number.
8T, 812T2, and 813T1) and DFT2 tumors (202T2, 203T3, 812T1, and 637T1) are
) and DFT2 hosts (202H1, 203H, 812H, and 637H) are displayed in black. The
L13A) and diagnostic amplification product for confirmation of DFT1 or DFT2
f an SRY band in DFT2 tumors infecting female Tasmanian devils.
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Figure 5. DFT1 and DFT2 Drug Screen
(A) Four DFT1 (85T, 86T, 87T, and 88T) and two DFT2 (203T3 and 809T) cell lines were screened against a panel of 104 drugs under clinical and pre-clinical
investigation in human oncology. Cell viability was measured after 144 hr.
(B) Hierarchical clustering of loge (IC50) values for 6 DFT cell lines (columns) screened with 104 compounds (rows).
(C and D) IC50 for DFT1 (blue) and DFT2 (red) cell lines for four receptor tyrosine kinase (RTK) inhibitors (C) or two DNA repair inhibitors (D). Gray dots represent
human cancer cell lines (GDSC set). Drug molecular targets are indicated. Horizontal bars represent geometric mean IC50. *p < 0.05, **p < 0.001; n.s., not
significant, Wilcoxon rank-sum test for DFT1 and DFT2 compared with human cell lines.
(E) Afatinib IC50 for 953 human cancer cell lines (All), 15 ERBB2-amplified human breast cancer cell lines (ERBB2
+ breast), and DFT1 and DFT2 cell lines.
Horizontal bars represent geometric mean IC50. **p < 0.001; n.s., not significant, Wilcoxon rank-sum test.
(F) Talazoparib IC50 for 922 human cancer cell lines (All), 21 Ewing’s sarcoma cell lines (Ewing’s), and DFT1 and DFT2 cell lines. Horizontal bars represent
geometric mean IC50. *p < 0.05, **p < 0.001; Wilcoxon rank-sum test.
See also Table S7.
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each year, this suggests that either such lesions are difficult to
detect or recognize or that DFT cancers arise rarely but carry a
high risk of becoming transmissible. Importantly, we cannot
completely negate the possibility that DFT1 and/or DFT2 arose
via a horizontal DNA transfer event involving an ancestral DFT
cell and a normal cell (Pye et al., 2016b); however, the lack of
germline and somatic genetic similarity between DFT1 and
DFT2 suggests that this scenario is unlikely.
We investigated genetic and phenotypic features of DFT1 and
DFT2, and compared the two lineages with each other and with
catalogs of known human cancer genes and drug sensitivity pro-
files. These data suggest an important role for RTK signaling,
most likely involving ERBB2 (DFT1 only) and PDGFRs (DFT1
and DFT2), in sustaining growth and survival of DFT cancers. In
this context, it is likely that copy number gains involving PDGFR
genes may have provided selective advantage in these cancers.
Furthermore, we noted thatPDGFRB has been amplified onDMs
in some DFT1s, and may be the positively selected driver
required to maintain this extrachromosomal DNA. We did not
identify anymutations in ERBB2 in DFT1. However, we observed
copy number gains involving ERBB3, encoding an ERBB2 heter-
odimerization partner, and NRG2, encoding an ERBB3 ligand
(Hynes and Lane, 2005; Taylor et al., 2017), suggesting a possible
mechanism for ERBB2 activation. Both DFTs show remarkably
few perturbations in known cancer genes, and only two genes
in DFT1 and five genes in DFT2 are predicted to have undergone
biallelic loss-of-function. Thus, the observation that DFT1 and
DFT2 both harbor predicted two-hit loss-of-function mutations
in genes encoding proposed regulators and effectors of Hippo
signaling (WWC3,MPDZ, TP73), togetherwith evidence for activ-
ity of Hippo effectors YAP1 and WWTR1/TAZ in DFT1 and DFT2
cells, raises the possibility that this pathway is involved in
DFT cancers in Tasmanian devils. The Hippo pathway plays
conserved roles in differentiation, proliferation, and regeneration
in several tissues (Moroishi et al., 2015;Yuet al., 2015; Zanconato
et al., 2016), and in the Schwann cell context drives transcrip-
tional upregulation of PDGF and ERBB signaling components
(Deng et al., 2017; Wu et al., 2018).
DFT clones must escape the host immune system despite
their status as allogeneic grafts. Although low Tasmanian devil
population genetic diversity may reduce capacity for foreign tis-
sue detection (Miller et al., 2011; Siddle et al., 2007), this species’
rejection of skin allografts (Kreiss et al., 2011) suggests that
DFT1 and DFT2 clones have specific adaptations favoring im-
mune escape. Our analysis did not identify any genomic aberra-
tions common to both cancers that might underlie such adapta-
tions, raising the possibilities that they may be epigenetically
controlled (Siddle et al., 2013), or that DFT cancers arise from
cell types that already harbor low immunogenicity. Nevertheless,
it is possible that hemizygous deletion of B2Mmay have contrib-
uted to downregulation of MHC class I in DFT1, although the re-
maining intact copy can be robustly expressed in response to the
inflammatory cytokine, interferon gamma (Siddle et al., 2013). In
DFT2, both copies of B2M remain intact, and B2M expression
has been detected in at least a subset of tumor cells (H. Siddle,
unpublished data). This suggests that DFT1 and DFT2 may have
adopted different strategies for immune evasion, although the
significance of these findings is not yet confirmed. Loss of Y
chromosome DNA in DFT2 may have rendered this cancer lessimmunogenic in female hosts, although we cannot exclude the
possibility that this loss is selectively neutral. If Y chromosome
loss is indeed a selective advantage to the lineage, we may
expect in future to observe Y-null DFT2 strains, perhaps derived
from several independent Y chromosome loss events, becoming
dominant in the population. Despite limited understanding of the
mechanisms of DFT immune evasion, recent observations of
natural immune responses against DFT1 (Pye et al., 2016a), as
well as allele frequency shifts indicative of selection in DFT1-
affected populations (Epstein et al., 2016), suggest that some
devils may be capable of mounting immune responses against
DFT cancers.
Altogether, our findings present the possibility that transmis-
sible cancersmay be a part of Tasmanian devils’ natural ecology.
Indeed, we did not find evidence for the involvement of exoge-
nous exposures or pathogens in DFT carcinogenesis, nor did
we identify any known cancer predisposition alleles in the in-
herited genomes of the DFT1 or DFT2 founder devils. Thus, it
seems plausible that additional DFTs occurred in the past but
escaped detection, perhaps because they remained in localized
populations or because they existed prior to the nineteenth-cen-
tury arrival of European documenters.
It is worth speculating about biological features specific to
devils that may spur DFT cancer development. Devils bite each
other frequently around the facial area, often causing significant
tissue injury (Hamede et al., 2013). Given the important roles for
Hippo and RTK signaling in wound-healing responses (Zanco-
nato et al., 2016), particularly in Schwann cells (Mindos et al.,
2017; Fex Svennigsen and Dahlin, 2013), it is tempting to spec-
ulate that DFT cancers may arise from aberrant maintenance of
proliferative cells involved in tissue repair after injury. Under this
model, the facial biting behavior of Tasmanian devils may predis-
pose these animals to emergence of cancers via tissue injury,
simultaneously providing a route of cell transmission. Further-
more, it is possible that anthropogenic factors may have indi-
rectly increased the risk of DFT emergence or spread in recent
years. For instance, it is possible that some modern land use
practices, such as pastoralism, may have provided favorable
conditions for devils, leading to elevations in local devil densities
(Guiler, 1970, 1982; Jones et al., 2004); this might have led to
increased intra-specific competition, perhaps increasing inter-
actions and fights, which may in turn have raised probabilities
of DFTs arising or spreading. Road construction may have
caused increased connectivity between devil populations,
providing more opportunities for DFTs to spread. Finally, perse-
cution of devils by European colonists (Hawkins et al., 2006) may
have contributed to this species’ low genetic diversity (Jones
et al., 2004), a possible risk factor for DFT immune escape and
disease spread (Siddle et al., 2007). In future, it will be important
to continue to monitor Tasmanian devils for evidence of addi-
tional DFT clones and to track the evolution and spread of
DFT1 and DFT2.
At present, there are few options for DFT treatment, and most
animals succumb to disease. Given the failure of conventional
chemotherapy agents against DFT1 (Phalen et al., 2013), the po-
tential for orally delivered, targeted therapies offer considerable
promise. We have shown that DFT1 and DFT2 are exquisitely
sensitive to a suite of RTK inhibitors, including those targeting
PDGFRs (DFT1 and DFT2) and ERBB2 (DFT1 only), as well asCancer Cell 33, 607–619, April 9, 2018 615
to inhibitors of DNA repair. The recent success of experimental
immunotherapy regimens against DFT1 (Tovar et al., 2017) opens
the possibility that therapies which combine RTK or PARP inhibi-
tion with immune activation may present new opportunities for
combatting DFT clones and saving the Tasmanian devil.
DFT1 and DFT2 arose from two unremarkable individuals,
which gave rise to cancers with strikingly similar, but subtly
different, histologic, genomic, and drug sensitivity phenotypes.
We have shown that, at least in Tasmanian devils, relatively sim-
ple genomic changes coupled with incessant growth factor
signaling spur the transition from somatic cell to parasitic clonal
lineage. Transmissible cancers in Tasmanian devils exploit a per-
verse niche created by their host species and illustrate one
context in which runaway selfish evolution can thrive.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Tissue Sampling and Ethics
Tissues were sampled from wild Tasmanian devils that were subsequently released, or from animals euthanized for welfare reasons.
All animal procedures were performed under a Standard Operating Procedure approved by the General Manager, Natural and
Cultural Heritage Division, Tasmanian Government Department of Primary Industries, Parks, Water and the Environment (DPIPWE),
in agreement with the DPIPWE Animal Ethics Committee, or under University of Tasmania Animal Ethics Committee Permit
A0014976. The project was approved by the University of Cambridge Department of Veterinary Medicine Ethics and Welfare
Committee, reference CR191.
Cell Lines and Cell Culture
DFT1 cell lines 86T and 88T have been previously described with the names 1426 and 4906 respectively (Siddle et al., 2013). DFT2
cell lines 202T2 and 203T3 cell lines were established as follows. Micro-biopsies of approximately 2 mm in diameter were collected
into RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) with 2% vol./vol. antibiotic-antimycotic (Thermo Fisher Scientific).
Biopsies were flushed through a tea-strainer sized metal mesh with amniomax (Thermo Fisher Scientific). Subsequently, cells
were plated in 6 well flat-bottomed plates (Corning Inc., Corning, NY, USA) with 3 ml amniomax and 2% vol./vol. antibiotic-antimy-
cotic, and placed at 35C with 5% atm. CO2. After 24 hr, medium was replaced and plates were incubated with the same conditions
for an additional 48 hr. Cells were then transferred into T25 flasks with the same medium, and after reaching confluence approxi-
mately 48 hr later, flasks were split and media changed to RPMI 1640; 1% vol./vol. GlutaMAX (Thermo Fisher Scientific); 10%
vol./vol. FCS (Bovogen Biologicals, Melbourne, VIC, Australia), 20% vol./vol. amniomax and 1% vol./vol. antibiotic-antimycotic.
We used MycoAlert (Lonza, Basel, Switzerland) and EZ-Mycoplasma Test (Biological Industries, Kibbutz Beit-Haemek, Israel) kits
to screen cell lines for Mycoplasma according to manufacturers’ instructions. Details about dates of sampling and Mycoplasma
status for cell lines sequenced in this study are indicated below.Name Year of Establishment Year of DNA Extraction Estimated Tumor Purity* Mycoplasma
86T 2005 2009 100% negative
88T 2007 2009 100% negative
202T2 2014 2015 100% positive
203T3 2014 2015 90-95% negative
*See SNV-based Tumor Purity Estimation for methods.Tables S1, S2, S6, and S7 and the Key Resources Table list information on all Tasmanian devil and DFT cell lines, as well as other
samples used in this study.
METHOD DETAILS
Cytogenetics
Chromosome-specific probes were derived from flow sorted chromosomes and hybridized with metaphases as described (Murch-
ison et al., 2012). For fluorescence in situ hybridization with telomeric probes, we used the Telomere PNA (Peptide Nucleic Acids)/Cy3Cancer Cell 33, 607–619.e1–e15, April 9, 2018 e4
kit (Dako, Glostrup, Denmark). There are two nomenclature systems in use for Tasmanian devil chromosomes (Deakin et al., 2012;
Pearse and Swift, 2006). These two systems differ in their designations of the two largest devil chromosomes, chromosomes 1 and 2.
The chromosome named chromosome 1 in the first system is named chromosome 2 in the second system, and vice versa. In this
study, we used the nomenclature adopted by Pearse and Swift (Pearse and Swift, 2006); this system is also used in the Tasmanian
devil reference genome (Murchison et al., 2012).
Histology
Tasmanian devil tissues were fixed in 10% Neutral Buffered Formaldehyde (Australian Biostain, Traralgon, VIC, Australia) for 24 hr
and selected tissues were cassetted (Techno Plas, St. Marys, SA, Australia) and processed overnight using a standard 15-hr
overnight procedure in the TP 1050 tissue processor (Leica Microsystems, Wetzlar, Germany). Tissues were orientated on the
EG1160 (Leica Microsystems), embedded in paraffin wax (Leica Microsystems) and sectioned at 3 microns using a Leica
RM2245 microtome and adhered to microscope slides (Menzel Gl€aser, Thermo Fisher Scientific) for 20 min at 60C. Sections
were deparaffinized, rehydrated and stained using Jung autostainer XL (Leica Microsystems) for Hematoxylin (Australian Biostain)
and Eosin, dehydrated, cleared, cover slipped (Leica Microsystems) and mounted in CV Mount (Leica Microsystems) (Hayes
et al., 2017).
Immunohistochemistry
Tasmanian devil tissues and tumors were sectioned at 3 microns, floated onto Superfrost plus slides (Menzel Gl€aser) and subjected
to standard deparaffinization and rehydration techniques using an automated stainer (Leica Microsystems). Antigen retrieval in tis-
sue sections was conducted in citrate buffer at pH 6.0 (Reveal Decloaker, Biocare Medical, Pacheco, CA, USA) at 120C for 8 min
using a Pascal pressure chamber (Dako) then cooled to 20C. Endogenous peroxidase activity was quenched using 3% hydrogen
peroxide (Ajax Finechem, Thermo Fisher Scientific) in methanol (Ajax Finechem) for 30 min. Detection of primary antibodies was
achieved using Mach1 Universal HRP-Polymer detection kit (Biocare Medical). Protein block (Background Sniper, Biocare Medical)
was applied for 20 min prior to application of primary antibodies. Polyclonal rabbit anti-human PDGFRA 1:800 (Cat#ab124392,
Abcam, Cambridge, UK), Monoclonal rabbit anti-human PDGFRB 1:50 (Cat#ab32570, Abcam), Polyclonal Rabbit anti-human
S100 1:1500 (Cat#Z0311, Dako), Monoclonal Mouse anti-human Neuron Specific Enolase 1:200 (Cat#M0873, Dako), Monoclonal
Mouse anti-human Cytokeratin 1:100 (Cat#M3515, Dako), Monoclonal Mouse anti-human Vimentin 1:800 (Cat#M0725, Dako),
Monoclonal Mouse anti-human Smooth Muscle Antigen 1:200 (Cat#M0851, Dako), Monoclonal Mouse anti-human Muscle Specific
Actin 1:50 (Cat#NCL-MSA, Leica Microsystems), Polyclonal Rabbit anti-human Periaxin 1:400 (Cat#HPA001868, Sigma-Aldrich,
St. Louis, MO, USA), Monoclonal mouse anti-human YAP1 1:100 (Cat#WH0010413M1, Sigma-Aldrich) and Polyclonal rabbit
anti-human WWTR1/TAZ 1:100 (Cat#T4077, Sigma-Aldrich) were diluted as indicated with antibody diluent (Dako) and applied
to both devil tumor and normal devil control tissues at room temperature for 30 min. Negative control was omission of primary anti-
body with buffer substitution. Universal HRP-polymer was applied for 30 min (MRH538L10, Biocare Medical) followed by 1 drop of
Betazoid DAB Chromogen 3,3 Diaminobenzidine (BDB900G, Biocare Medical) in 1 ml of substrate buffer (DB900, Biocare Medical)
applied for 4 min. Tris-buffered saline (Biocare Medical) was used to rinse between all steps. Slides were rinsed, stained with
Carazzi’s Hematoxylin for 5 min, washed for 3 min in tap water, dehydrated, cleared, cover slipped (CV5030, Leica Microsystems)
and mounted in CV mount (Leica Microsystems) (Hayes et al., 2017). Sections were viewed under light microscopy using Olympus
BX41 (Olympus Corporation, Shinjuko, Tokyo, Japan) and selected areas were photographed using a digital camera (DP20,
Olympus Corporation).
Sample Processing and Sequencing
DNA Extraction
DNA from all samples except for 86T and 88T was extracted using the DNeasy Blood and Tissue extraction kit (Qiagen, Hilden,
Germany). DNA from 86T and 88T was extracted using the Genomic-Tip kit (Qiagen).
Library Preparation
500 ng of genomic DNA was fragmented (average size distribution 425 base pair (BP), LE220, Covaris, Woburn, MA, USA), purified,
libraries prepared (Agilent SureSelect XT, HSQ, Agilent Technologies, Santa Clara, CA, USA), and index tags applied (Sanger 168 tag
set). Index tagged samples were amplified (6 cycles of PCR, KAPA HiFi kit, KAPA Biosystems, Wilmington, MA, USA), quantified
(1k assay, LabChip GX, PerkinElmer, Waltham, MA, USA), then pooled together in an equimolar fashion.
High-Coverage DNA Sequencing
Pooled samples were quantified (1K assay, Bioanalyzer, Agilent Technologies), normalized (6 nM), and submitted to cluster
formation for HiSeq V4 sequencing (125 BP paired-end (PE) reads, Illumina, San Diego, CA, USA). We sequenced the equivalent
of two lanes per tumor, and one lane per host; however, sequencing was multiplexed across several lanes. The table below
indicates average insert size, read length and average read depth for samples sequenced at high coverage in this study (see
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ID Average Sequencing Depth Average Insert Size Read Length
202H1 49 X 417 BP 125 PE
202T2 67 X 418 BP 125 PE
203H 45 X 428 BP 125 PE
203T3 70 X 429 BP 125 PE
86T 86 X 430 BP 125 PE
88T 67 X 428 BP 125 PESequence reads were aligned to the Tasmanian devil reference genome Devil7.1, an in-house assembly which is identical to the
publicly available Devil7.0 (http://www.ensembl.org/Sarcophilus_harrisii/Info/Index), except Devil7.1 excludes the mitochondrial
contig. Throughout the study, we used custom scaffold identifiers. Correspondence between our scaffold identifiers and those
used in Devil7.0 can be found at Mendeley Data (https://doi.org/10.17632/znfphvhmbv.1). Alignment was performed using BWA-
backtrack (Li and Durbin, 2009) and duplicate flagging and removal was conducted using PICARD (DePristo et al., 2011).
Low-Coverage DNA Sequencing
Thirty normal genomes were additionally sequenced at low coverage (1 X) (Table S2). Library preparation and sequencing were
performed as described for high-coverage genomes. Reads were aligned to Devil7.1+MT with BWA-MEM.
Published Normal Devil Genomes
We included data from two previously sequenced normal Tasmanian devil genomes, 31H and 91H, in this study ((Murchison
et al., 2012); 31H and 91H are the ‘‘male’’ and ‘‘female’’ normal genomes respectively). However, only a subset of 31H
data (lanes 999#1, 999#2, 999#3, 999#4, 999#6, 1000#1, 1000#2, 1000#4, 1000#6, 1000#7, 1000#8, 1002#1, 1002#7, 1003#1,
1003#2, 1003#3, 1003#7) were included, as some lanes fell below sequencing quality thresholds (average sequencing coverage
for this sample was 17 X). Two previously sequenced DFT1 tumors from this study, 53T and 87T (Murchison et al., 2012), were
not included in the current study, as they fell below sequencing quality thresholds. Twelve previously sequenced devil normal
genomes were also used in this study (Wright et al., 2017) (Table S2). These were aligned to Devil7.1+MT with BWA-MEM.
Whole Genome Amplification
Whole genome amplification was performed to create DNA stocks for PCR screening. Depending on the concentration, 1-2 ml of
DNA (concentration range 20 to 50 ng/ml) from each sample was used as input for whole genome amplification using the illustra
GenomiPhi V2 DNA Amplification kit (GE Healthcare, Chicago, IL, USA).
SNV Validation
We performed experimental validation on a set of 96 single-nucleotide variants (SNVs) obtained through our computational filtering
pipelines. The SNVs selected for validation were derived from computation sets found in both DFT1s (86T and 88T), both DFT2s
(202T2 and 203T3) or in all four tumors (86T, 88T, 202T2, 203T3). Primers were designed around each SNV (Table S2) and used
to amplify a 500 BP region around the SNV site with conditions as follows. Template DNA was an equal volume pool of whole
genome amplified DNA from 86T, 88T, 202T2 and 203T3.Ingredient Company Volume (ml)
Water - 6.2
Phusion HF buffer (5x) Thermo Fisher Scientific 4.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 3.0
Primer reverse (10 mM) Sigma-Aldrich 3.0
Template DNA - 2.0
Phusion HF Polymerase Thermo Fisher Scientific 0.2
Total - 20.0
Step Duration (s) Cycles
Initial melting (98C) 300 1
Melting (98C) 30
35Annealing (60C) 30
Elongation (72C) 45
Final elongation (72C) 300 1
Final cooling (4C) - 1
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Amplification products were purified with the QIAquick PCR purification kit (Qiagen), and pooled in roughly equimolar quantities.
Pooled amplicon DNA was quantified (dsDNA BR assay, Thermo Fisher Scientific), purified, libraries prepared (NEBNext Sanger
Sequencing Kit, New England Biolabs, Ipswich, MA, USA), and index tags applied (Sanger 168 tag set). Index tagged samples
were amplified (8 cycles of PCR, KAPA HiFi kit, KAPA Biosystems), quantified by qPCR (KAPA Library Quant Kit, KAPA Biosystems)
and submitted to cluster formation for MiSeq sequencing (300 BP PE read length, Illumina).
12,831,254 sequence readswere obtained and aligned to 2000BPwindows around each of the 96SNV loci in theDevil7.1 reference
usingBWA-MEM (Li, 2013); the95 loci (onePCR failed) hadamedian readcoverageof 70,941X (range1,730X to481,111X).Wemanu-
ally inspected each of the 95 loci using the Integrative Genomics Viewer (IGV) (Thorvaldsdo´ttir et al., 2013) to ensure alignment accu-
racy. As the template DNA used in this experiment was a pool of DNA from four tumors, and each SNVwas predicted to be present, at
least in the heterozygous state, in at least two of the four tumors, theminimum variant allele fraction (VAF), for the predicted alternative
allelewasexpected tobe0.25. In order to distinguish truealleles frombackground sequencing errors,wefirst usedalleleCount (https://
github.com/cancerit/alleleCount) to calculate VAF for the two nucleotide bases that were neither the reference allele nor predicted
alternative allele. We fitted a gamma distribution to these ‘‘background VAFs’’ and used this distribution to test if our predicted alter-
native allele VAF was significantly different to background. Predicted alternative alleles with VAF values that fell above 95% of the cu-
mulative probability under the gammacurvewere defined as validatedSNVs.Overall, 93/95 SNVswere validated, detailed in TableS2.
SNV Genotyping across Normal Panel
We PCR screened each of the 93 validated SNVs across a panel of 30 normal devils to confirm genotyping accuracy. Whole genome
amplified DNA from 30 devils was distributed with equal volume into three pools of 10 devils (Table S2). PCRs were performed, am-
plicons were pooled, libraries prepared and MiSeq sequencing performed (see section SNV Validation) with 300 BP PE reads.
12,116,462 sequence reads were generated, and mapped to 2000 BP windows around each of the 95 SNV loci in Devil7.1 using
BWA-MEM (Li, 2013) with a median read depth of 80,778 X (range 1,594 X to 328,569 X). Using the same approach outlined above
(see section SNV Validation), we obtained the classification results summarized in Table S2.
SNV Genotyping ofWWC3 and MPDZ Mutations
To assess the somatic pervasiveness of hemizygous WWC3 SNV (DFT1) and MPDZ indel (DFT2) predicted loss-of-function muta-
tions, we used the following sequencing approach. We PCR amplified (primers WWC3 forward and WWC3 reverse, see Key Re-
sources Table) a 200 BP region around the affected WWC3 locus on exon 21 in ten tumors 36T2, 85T, 86T, 87T, 88T, 95T, 96T,
221T, 331T and 333Ta which cover a wide spatiotemporal range (Table S2). Similarly, a region around the frameshift MPDZ indel
on exon 9 was amplified (primers MPDZ forward and MPDZ reverse, see Key Resources Table) in the four DFT2 tumors 202T2,
203T3, 338T and 339T (Table S2). PCR products were cleaned up with the QIAquick PCR Purification kit (Qiagen). Products were
then capillary sequenced with the corresponding PCR primers WWC3 forward and MPDZ forward (Key Resources Table).Ingredient Company Volume (ml)
Water - 5.5
PCR buffer (10x) Qiagen 5.0
dNTP-mix (2.5 mM each) Qiagen 4.0
Primer forward (10 mM) Sigma-Aldrich 7.5
Primer reverse (10 mM) Sigma-Aldrich 7.5
Template DNA - 20.0
Taq Polymerase Qiagen 0.5
Total - 50.0
Step Duration (s) Cycles
Initial melting (94C) 300 1
Melting (94C) 30
35Annealing (58C) 30
Elongation (72C) 15
Final elongation (72C) 300 1
Final cooling (4C) - 1SV Validation
Candidate Structural Variants (SVs) were validated with PCRs spanning breakpoints. PCR primers are listed in Table S5, and PCR
conditions are listed below. Of the 345 candidate SVs, 345 (100%) were validated (Table S5). Candidate somatic SV amplicons
were sequenced on the Illumina MiSeq platform. Amplicons were purified and libraries generated as described above in SNV Vali-
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Ingredient Company Volume (ml)
Water - 8.3
CoralLoad buffer (10x) Qiagen 2.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 3.0
Primer reverse (10 mM) Sigma-Aldrich 3.0
Template DNA - 2.0
Taq Polymerase Qiagen 0.1
Total - 20.0
Step Duration (s) Cycles
Initial melting (94C) 300 1
Melting (94C) 30
35Annealing (60C) 30
Elongation (72C) 90
Final elongation (72C) 300 1
Final cooling (4C) - 1SV Genotyping across Normal Panel
We screened all PCR validated SVs across a panel of 34 normal devil genomes. Briefly, whole genome amplified DNA from 34 devils
was pooled in equal volume into four pools (3 pools of 10 devils, and 1 pool of 4 devils that comprised DNA from 202H1, 203H, 31H
and 91H; Table S2) and PCRs were conducted with the reagents and conditions as described above (see section SV Validation). SVs
that amplified in any one of the normal pools were classed as germline, and those which were not amplified in any of the normal pools
were retained as candidate somatic. The SVs predicted to be unique to a single tumor were validated by confirming their absence by
PCR in other tumors (Table S5).
SV Genotyping of PDZD11-RFX2
In order to establish the somatic pervasiveness of a detected intron-to-intron structural variant interlinking genes PDZD11
and RFX2 across the DFT1 tumor phylogeny, we used a similar PCR strategy as described above for the WWC3 and MPDZ
mutation screening. Briefly, a 231 BP amplicon involving breakpoints on chromosomes 2 and X, was obtained in eight additional
DFT1 tumors 36T2, 85T, 87T, 95T, 96T, 221T, 331T and 333Ta (Table S2). Primers used were PDZD11-RFX2 forward and
PDZD11-RFX2 reverse (Key Resources Table), and PCR conditions are listed below.Ingredient Company Volume (ml)
Water - 5.3
CoralLoad buffer (10x) Qiagen 2.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 3.0
Primer reverse (10 mM) Sigma-Aldrich 3.0
Template DNA - 5.0
Taq Polymerase Qiagen 0.1
Total - 20.0
Step Duration (s) Cycles
Initial melting (94C) 300 1
Melting (94C) 30
35Annealing (60C) 30
Elongation (72C) 30
Final elongation (72C) 300 1
Final cooling (4C) - 1
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DFT Diagnostic PCRs
A multiplex DFT diagnostic PCR has been developed to confirm DFT1 or DFT2 diagnosis (Kwon et al., 2018). Briefly, the PCR incor-
porates three primer sets, respectively targeting a DFT1-specific structural variant, a DFT2-specific structural variant, and the
RPL13A locus, which acts as an internal positive control. The PCR was performed as described (Kwon et al., 2018).
Y Chromosome PCRs
Samples included in this analysis are listed in Table S6. Whole genome amplified DNA was used as a template for amplification of
SRY or a set of DFT1/DFT2 diagnostic markers as follows with primers SRY forward and SRY reverse (Key Resource Table).Ingredient Company Volume (ml)
Water - 11.3
PCR buffer (10x) Qiagen 2.0
dNTP-mix (10 mM each) Thermo Fisher Scientific 1.6
Primer forward (10 mM) Sigma-Aldrich 1.5
Primer reverse (10 mM) Sigma-Aldrich 1.5
Template DNA - 2.0
Taq Polymerase Qiagen 0.1
Total - 20.0
Step Duration (s) Cycles
Initial melting (94C) 300 1
Melting (94C) 30
38Annealing (64C) 30
Elongation (72C) 90
Final elongation (72C) 300 1
Final cooling (4C) - 1Drug Screen
Automated High-throughput Screen
Details of cell lines used in drug screen are presented in Table S7. Cells were seeded into 384-well plates using a XRD-384 (FluidX,
Brooks Automation, Chelmsford, MA, USA) reagent dispenser. The number of cells seeded was individually optimized for each cell
line to maximize the dynamic range of the assay: 85T = 600, 86T = 1200, 87T = 2000, 88T = 1600, 203T3 = 3200, 809T = 1600. Com-
pounds were stored in Storage Pods (Roylan Developments, Fetcham, UK) providing a moisture-free, low oxygen environment, and
protection from UV damage. Compounds were screened using a 7-point dose response curve and a linear half-log dilution series
covering a 1000-fold concentration range. The dosing of the compounds was carried out using an Echo 555 (Labcyte, San Jose,
CA, USA) acoustic dispenser and the duration of drug treatment was 144 hr (6 days). Cell number at the end of 6 days was measured
using CellTitre-Glo 2.0 (Promega, Madison, WI, USA) reagent. 85T, 86T, 87T and 88T cell lines were screened as a single technical
replicate in each of two separate screening runs. 203T3 cell line was screened in duplicate in each of two separate screening runs.
809T was screened in duplicate in each of two separate screening runs for a proportion of compounds, and was screened as a single
replicate on the remaining proportion of compounds. Fluorescence intensity data from screening plates for each dose response
curve was fitted using a multi-level fixed effect model (Vis et al., 2016).
Manual Follow-up Screen
We performed a follow-up drug screen to further elucidate the drug sensitivity of DFT1 cell lines to dual EGFR and ERBB2 inhibitors.
Specifically, DFT1 showed particular sensitivity to Afatinib, an inhibitor of both ERBB2 and EGFR (Table S7). The observation that
DFT1 cell lines were resistant to Gefitinib, an inhibitor of EGFR, suggests that the sensitivity to Afatinib is mediated by ERBB2.
We further tested this hypothesis bymanually screening DFT1 cell lines (85T, 86T, 87T, 88T) and three human cancer cell line controls
(A549, AU565 and PC-9) with Erlotinib and Gefitinib (EGFR inhibitors), and Lapatinib and Afatinib (EGFR and ERBB2 inhibitors), as
displayed in Table S7.
The control human cancer cell lines have the following known sensitivities. PC-9 has a drug sensitive deletion in EGFR (E746-A750
in exon 19) and is thus susceptible to EGFR inhibitors (Bean et al., 2007; Li et al., 2008). PC-9 cells are known to be highly sensitive
to Gefitinib, Afatinib, and Erlotinib while exhibiting only a very modest sensitivity to Lapatinib (Bean et al., 2007). AU565 is an ERBB2-
dependent breast cancer cell line and as such is sensitive to the ERBB2 inhibitors Afatinib and Lapatinib, but is insensitive to drugs
targeting only EGFR. A549 is a human lung adenocarcinoma cell line with an oncogenic KRAS G12S point mutation, displaying
resistance to both EGFR and ERBB2 inhibitors (Li et al., 2008). DFT1 cell lines and A549 were grown in DMEM/F-12 media,
AU565 and PC-9 were grown in RPMI-1640 media. All cells were maintained at 37C and 5% CO2.e9 Cancer Cell 33, 607–619.e1–e15, April 9, 2018
Dose-response curves were obtained by setting up 96-well cell culture plates for each drug. DFT1 cells in each well were dosed
with drugs at exponentially decreasing concentration. The maximum drug concentration was 1 mM. The cells were cultured in the
presence of drugs for 48 hr. A fluorescence-based live-cell assay (Thermo Fisher Scientific) was used to detect cell viability. After
live-cell detection, the cells were fixed overnight. On the next day, the cells were prepared for fixed cell detection. Cells were washed
two times with 200 ml/well of water and stained with Syto60 1:5000 (Thermo Fisher Scientific). After 1 hr of incubation at room tem-
perature, plates were washed two times with 200 ml/well of water. Lastly, 100 ml of water was added to each well and the plate was
detected. The experiment was repeated in triplicates for each cell line and drug. IC50 values from this experiment are shown below as
loge(mM) concentrations, indicate that DFT1 is resistant to Erlotinib, and that 3 of 4 DFT1 cell lines here tested show sensitivity to
Lapatinib under these conditions (Table S7).
QUANTIFICATION AND STATISTICAL ANALYSES
Bioinformatics downstream analyses of ancestral data, mutational calls and drug screen results were performed in the R language for
statistical computing (R Core Team, 2015), using existing Bioconductor libraries (Huber et al., 2015) and customized scripts.
Devil Population Analysis
Wegenotyped tumors 86T and 88T (DFT1), tumors 202T2 and 203T3 (DFT2), and normal devils 202H1, 203H and 91H against a panel
of previously ascertained variants (Br€uniche-Olsen et al., 2016). Of the 2,281 variants described by Br€uniche-Olsen et al., we
excluded (i) indels, (ii) single nucleotide polymorphisms (SNPs) falling into RADseq-fragments ambiguously mapping to the reference
genome (i.e. >2 mismatching bases or one or more alignment gaps of total length >2 BP), (iii) SNPs mapping in windows of 5 BP
around simple repeats, 500 BP around contig ends or 1,000 BP around scaffold ends, (iv) SNPs mapping to the X chromosome
and (v) SNPs falling into regions which are non-diploid in any of the tumor samples (Table S4). In addition, using the genotypes pro-
vided by Br€uniche-Olsen et al., we excluded those SNPs which showed limited variation across the population. Specifically, for each
SNP we computed the proportion of individuals that shared identical genotypes. SNPs were ranked by the proportion of individuals
sharing identical genotypes, and those SNPs which were within the group of 60% least varying across the population were excluded.
Finally, if >1 SNPmapped to the same RADseq fragment, only the SNPmapping closest to the 5’ end of the fragment (with respect to
the reference) was selected for further analysis. These steps provided a final set of 320 SNPs.
Of the 527 individuals genotyped in (Br€uniche-Olsen et al., 2016), we excluded any individual with missing genotype data at more
than 20%of loci. For the remaining 398 individuals, we extracted the genotypes assigned in (Br€uniche-Olsen et al., 2016). Genotypes
across DFT1 tumors 86T and 88T, DFT2 tumors 202T2 and 203T3, as well as normal devils 91H, 202H1 and 203H were genotyped
at the 320 SNP loci using alleleCount (https://github.com/cancerit/alleleCount). Sites with <7 read coverage were marked asmissing
data, and remaining sites were coded as follows:
(i) homozygous 1/1: >70% reads support allele 1
(ii) heterozygous 1/2: >30% and <70% reads support alleles 1 and 2
(iii) homozygous 2/2: >70% reads support allele 2
Our 1 and 2 allele definitions were used as per Br€uniche-Olsen et al. (2016). Missing genotypes across all 405 individuals were
imputed by adopting the genotypes of the closest related SNP, as measured by Euclidian distance across the sample set.
Hierarchical clustering was then performed by applying the default R hclust() function (method: ’complete’), defining each geno-
type value as follows:
(i) homozygous 1/1: 0
(ii) heterozygous 1/2: 0.5
(iii) homozygous 2/2: 1SNV and Indel Analysis
SNV and Indel Calling
We used Platypus version 0.8.1 for detecting and genotyping single nucleotide variants (SNVs) and small insertions and deletions
(indels) (Rimmer et al., 2014). Variants were ascertained from the high-coverage genomes sequenced in this study (86T, 88T,
202T2, 203T3, 202H1, 203H) as well as from two previously sequenced devil genomes (31H, 91H) (Tables S1 and S2). Platypus
was run twice on each BAM file with two different settings: (i) default mode with additional flags –minReads=3 and –minPosterior=0,
(ii) default mode with –minReads=3, –minPosterior=0, –minFlank=0 and –trimReadFlank=10. Variants flagged with badReads, MQ,
strandBias, SC and QD were removed, and remaining variants were merged into a single file and genotyped across each sample.
Genotyped variants flagged with badReads, MQ, strandBias, SC and QD were removed for both SNVs and indels. The final variant
list contained 1,882,666 SNVs and 356,570 indels genotyped across the set of tumors (86T, 88T, 202T2, 203T3) and hosts (202H1,
203H, 91H, 31H). The following post-processing steps were applied to our set of genotyped SNVs and indels.Cancer Cell 33, 607–619.e1–e15, April 9, 2018 e10
(i) Homozygous-variant-in-reference filter. Sample 91Hwas used to assemble the Tasmanian devil reference genome (Murchison
et al., 2012). This implies that variants called with a high variant allele fraction (VAF, proportion of reads at a base position
supporting the variant allele) in this sample are likely to represent reference assembly errors. Thus, SNVs and indels called
with VAF >0.9 in sample 91H were discarded from our variant list.
(ii) Strand bias filter. In regions with total coverage R11 across all eight samples, we rejected variant calls with less than 20%
support on either forward or reverse sequencing strands. In regions with total coverage <11 reads across all samples, we
removed variants that had less than two supporting reads in either forward or reverse direction.
(iii) Sequencing noise filter. Low-VAF SNVs and indels were found across all samples, including hosts, and therefore likely reflect
consistent sequencing noise or alignment artefacts in these positions. A variant with VAF <0.2 in all samples withR1 support-
ing reads was discarded if at least one of the host samples hadR1 supporting reads.
(iv) Simple repeats regions filter. SNVs and indels lying within a 5 BP window around simple repeat regions, as annotated by Tan-
dem Repeat Finder (Benson, 1999), were discarded.
(v) Regions filter. The Tasmanian devil reference genome (Devil7.1) is a scaffold-level assembly, consisting of 237,291 contigs
assembled into 35,974 scaffolds. We rejected any variant mapping within 500 BP from the start or end of a contig, or within
1000 BP from the start of end of a scaffold. In addition, variant calls mapping to scaffolds not assigned to a chromosome were
discarded.
Combined, these filtering steps left 988,972 SNVs and 194,250 indels. We further genotyped these across our panel of 30 low-
coverage normal devil genomes and 12 previously published normal devil genomes (Wright et al., 2017) using Platypus with settings
–minPosterior=0 and –minReads=0.
SNV and Indel Subsetting
We classified our variants into different categories, outlined below. Number of variants in each set is indicated in table below.
(i) Germline variants, which are present in the Tasmanian devil population, were defined as variants which had R5 supporting
sequence reads in high-coverage normal genomes 91H, 202H1 or 203H, or R1 supporting sequence read in genome 31H
and 42 low-coverage normal genomes (samples listed in Table S2).
(ii) Potentially somatic variants are shared between both tumors of the same lineage, or all four tumors, withR5 reads in each
tumor, but have <5 reads in each of the three high-coverage normal devil genomes 91H, 202H1 and 203H, and 0 reads in
genome 31H and 42 low-coverage normal devil genomes (Table S2). This set includes the following three subsets:
DFT1 Potentially Somatic Variants. Present withR5 reads in 86T and 88T, but%5 reads in DFT2 tumors and 202H1, 203H and 91H
normal devil genomes, and 0 reads in genome 31H and 42 low-coverage normal devil genomes (Table S2). These represent both
germline variation that was inherited by the DFT1 founder devil, but that is not captured in the DFT2 founder devil, nor in the normal
genomes examined here; and somatic variants that were acquired before divergence of 86T and 88T.
DFT2 Potentially Somatic Variants. Present with R5 reads in 202T2 and 203T3, but %5 reads in DFT1 tumors and normal devil
genomes 202H1, 203H and 91H, and 0 reads in genome 31H and 42 low-coverage normal devil genomes (Table S2). These represent
both germline variation that was inherited by the DFT2 founder devil, but that is not captured in the DFT1 founder devil, nor the normal
genomes examined here; and somatic variants that were acquired before divergence of 202T2 and 203T3.
DFT1 and DFT2 Potentially Somatic Variants. Present withR5 reads in 86T, 88T, 202T2 and 203T3, but%5 reads in normal devil
genomes 202H1, 203H and 91H, and 0 reads in genome 31H and 42 low-coverage normal devil genomes (Table S2). These poten-
tially represent both germline variation that was inherited by both the DFT1 and DFT2 founder devil, but that is not captured in the
normal genomes examined here; and somatic variants that were acquired by DFT1 before the divergence of 86T and 88T, and
were also independently acquired by DFT2 before the divergence of 202T2 and 203T3.
(iii) Tumor-unique variants are those variants that are present withR5 reads in only one tumor, and are supported by <5 reads in
every other tumor and normal genomes 91H, 202H1 and 203H, as well as 0 reads in genome 31H and 42 additional normal
genomes (Table S2). These variants could be newly arising somatic mutations that occurred after divergence of 86T-88T or
202T2-203T3 from their most recent common ancestor (MRCA) tumors; or germline variants inherited by the DFT1 or DFT2
founder devils but not shared with the normal panel, or somatic mutations that arose before the MRCA of 86T-88T or 202T2-
203T3, that were subsequently lost in one tumor due to back mutation or copy number loss.
(iv) Remainder variants comprise SNVs or indels which are either (i) represented by support fromR5 reads in at least one DFT1
and one DFT2 tumor, but not found withR5 reads in all four tumors, not found withR5 reads in any high-coverage normal
genomes (202H1, 203H, 91H) or with >0 reads in 31H and 42 low-coverage hosts (Table S2); or (ii) supported by <5 reads in
ascertainment panel samples (86T, 88T, 202T2, 203T3, 202H1, 203H, 91H).
The table below indicates number of variants belonging to each category outlined above. Panels on right indicate with ‘‘x’’ the
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Set SNVs Indels 86T 88T 202T2 203T3 Normal Devils
Total 988,972 194,250
Germline 974,040 191,001 x x x x x
DFT1 potentially somatic
DFT2 potentially somatic
DFT1/DFT2 potentially somatic
2,796
3,503
88
387
549
23
x
-
x
x
-
x
-
x
x
-
x
x
-
-
-
86T tumor-unique
88T tumor-unique
202T2 tumor-unique
203T3 tumor-unique
3229
3583
231
398
477
566
19
66
x
-
-
-
-
x
-
-
-
-
x
-
-
-
-
x
-
-
-
-
Remainder 1,104 1,162 x x x x xGenome browser visual assessments of 75 individual variant calls yielded false positive call rates of <5% for SNVs (2/75) and <15%
for indels (9/75).
SNV and Indel Annotation
Of the 602 genes in the COSMIC Cancer Gene Census (http://cancer.sanger.ac.uk/census/; downloaded on 17/05/2016), 490 were
annotated in the Ensembl Devil7.0 genebuild (http://www.ensembl.org/Sarcophilus_harrisii/Info/Index). An additional 69 genes were
annotated only in the NCBI 101 annotation gene set (https://www.ncbi.nlm.nih.gov/genome/annotation_euk/Sarcophilus_harrisii/
101/; downloaded on 17/05/2016), but were not in the Ensembl gene set; thus, 43 cancer geneswere not detectable in the Tasmanian
devil reference genome (Table S3). SNV and indel subsets were annotated with the Ensembl variant effect predictor (VEP) using
default settings (McLaren et al., 2010) (Tables S2, S3, and S4). We also ran an alternative variant caller, SAMtools mpileup, specif-
ically on the COSMIC Cancer Gene Census gene set (Table S3) and searched manually for additional protein-altering variants, how-
ever, this did not detect additional variants.
SNV-Based Tumor Purity Estimation
Tumor DNA sequenced in this study was derived from cell lines, and thus is likely to be relatively pure. However, it is possible, partic-
ularly for early passage cell lines, that host cells remain in culture. We assessed the purity of 86T, 88T, 202T2 and 203T3 by examining
VAF of germline SNVs. This analysis revealed that 86T, 88T and 202T2 contain only tumor DNA, whereas 203T3 had approximately
5-10% host DNA at the time when DNA was collected for sequencing.
Copy Number Analysis
Scaffold Exclusion
The Tasmanian devil genome Devil7.1 has 35,974 scaffolds, most of which are assigned to chromosomes (Murchison et al., 2012),
with scaffolds ordered along chromosomes using synteny with the opossum genome (Mikkelsen et al., 2007; Murchison et al., 2012).
Short scaffolds, for which synteny with the opossum genome could not be determined, are placed at the end of each chromosome.
We excluded these latter scaffolds from copy number analysis, together with the entire X chromosome. Coordinates of excluded
scaffolds are listed below.Chromosome Excluded Scaffolds
1 Chr1_supercontig_000000399 to Chr1_supercontig_000006728
2 Chr2_supercontig_000000501 to Chr2_supercontig_000008380
3 Chr3_supercontig_000000417 to Chr3_supercontig_000007196
4 Chr4_supercontig_000000317 to Chr4_supercontig_000006728
5 Chr5_supercontig_000000218 to Chr5_supercontig_000003187
6 Chr6_supercontig_000000194 to Chr6_supercontig_000002843
X Chrx_supercontig_000000000 to Chrx_supercontig_000002377
Un ChrU_supercontig_000000000 to ChrU_supercontig_000000439Copy Number Calling
We used the read-depth based algorithm cn.MOPS to assign copy numbers to genomic segments of our four high-coverage tumor
genomes (Klambauer et al., 2012). Samples 91H, 202H1 and 203H served as normal controls. Briefly, read-depths were counted in
500 BP bins across selected scaffolds using cn.MOPS getReadCountsFromBAM(), and coverage was normalized to the mode. After
modelling copy number posterior likelihoods between copy number (CN) 0 and CN6 for each 500 BP bin in each sample, the
cn.MOPS circular binary segmentation algorithm was invoked with a 3 x 500 BP minimum length parameter for non-CN2 segments.Cancer Cell 33, 607–619.e1–e15, April 9, 2018 e12
Copy Number Filtering
Each candidate copy number variant (CNV) (defined as a segment with CNs2) was filtered through a number of steps. First, the min-
imum size of copy number changes specific to a unique tumor within either the DFT1 or DFT2 lineage (tumor-unique CNVs) was set to
5000 BP, i.e. at least 10 neighboring bins of 500 BP. To further validate tumor-unique CNV segments, we conducted quantitative,
lineage-specific sequence read count comparisons. CNVs were only retained when their dispersions significantly differed
(p<0.01) between 86T-88T or 202T2-203T3, as measured by a paired two-sided Student’s t-test. For segments with insignificantly
differing read count distributions, copy number posterior likelihoods from cn.MOPS were pooled between both tumors. The highest
scoring median value was then chosen for assigning the same segmental copy number to both 86T and 88T or 202T2 and 203T3.
Table S4 lists copy number segments and assignments.
Copy Number Annotation
Non-diploid copy number segments were intersected with the set of Ensembl genes (Devil7.0) (Tables S3 and S4). Genes that were
completely or partially represented on non-diploid segments, such that loss of one copy or gain of one ormore copies was predicted,
were considered to be involved in a CNV (Figure 4A, Tables S3 and S4).
To validate gene copy number annotations in COSMIC Cancer Gene Census genes (http://cancer.sanger.ac.uk/census/; down-
loaded on 17/05/2016), and to obtain calls of those COSMIC genes falling into previously excluded scaffolds (seeScaffold Exclusion),
and which are not annotated by Ensembl, we conducted an independent, parallel copy number assessment (Table S3). 559/602
COSMIC Cancer Gene Census genes are annotated in the devil reference genome in the Ensembl and/or NCBI gene sets (see
SNV and Indel Annotation). To search for the remaining 43 genes, which were annotated neither by Ensembl nor NCBI, we obtained
transcript sequences for each gene’s opossum – or if this was not available – human orthologue. We used BLAT (Kent, 2002) to align
the gene transcript to the devil genome; this approach allowed us to preliminary annotate an additional 4 genes. Next, each gene’s
footprint was defined as the genomic interval between the start of the first exon and the end of the last exon of each gene. Gene
footprints were divided into bins of 500 BP, or – in the case when the gene region would be partitioned into fewer than 10 bins –
into bins of 50 BP. For each bin in each sample, the average coverage was collected from the aligned reads using the SAMtools
bedcov function (Li et al., 2009). Samples were divided into the following groups: DFT1 (86T, 88T), DFT2 (202T2, 203T3) and host
(31H, 91H, 202H1, 203H). An ANOVA test was used to identify gene loci with a heterogeneous distribution of coverage, where the
mean of one group differed significantly from the other two with a confidence level of 0.0001. Tukey’s range test was then performed
to establish which samples had a different mean. A threshold difference of 0.25 was used in order to call a copy number gain or loss
after a significant difference was determined. This threshold was also used to assign individual copy number variants to specific
samples.
CNV Genotyping across Normal Panel
We analyzed copy number changes on chromosome 3 in our panel of 46 normal devil genomes as follows. Sequencing reads falling
into 10,000BPwindows tiled along the chromosomewere counted by cn.MOPS getReadCountsFromBAM() (Klambauer et al., 2012).
Bin counts were normalized by the average sequencing depth across the whole respective sample, as listed in Table S2.
Structural Variant Analysis
Structural Variant Calling
We used Breakpoints via Assembly (BRASS), a tool that uses discordantly mapped read pairs, for detecting structural variants (SVs).
Aminimumof two discordant reads detecting a breakpoint in any one sample was required tomake a call. SVs were ascertained from
tumors 86T, 88T, 202T2 and 203T3, and normal genomes 91H, 31H, 202H1 and 203H.
Structural Variant Filtering
We rejected SV calls for which at least one end fell within a scaffold not assigned to a chromosome. Only calls with a total of >10
supporting reads across all eight samples (86T, 88T, 202T2, 203T3, 31H, 91H, 202H1, 203H) were retained. Moreover, any SV pre-
diction with >2 combined supporting reads across any of the four normals 31H, 91H, 202H1, and 203H was discarded as a likely
germline polymorphism. Somatic and potentially somatic SVs were defined as having >10 supporting reads in individual tumors
or both tumors of a lineage respectively, together with <3 supporting reads in all other samples combined.
Structural Variant Display
Circos plots of the set of SVs that were not detected in the normal panel are displayed in Figure 3B using the R circlize package (Gu
et al., 2014).
Structural Variant Breakpoint Assembly
Exact breakpoint types and corresponding single-base resolution were reconstructed through an in-house analysis pipeline centered
around the TIGRA assembler (Chen et al., 2014). Briefly, the structural variant breakpoint predictions identified by BRASS were given
as input to TIGRA. TIGRA was used to select structural variant-supporting reads from tumors (86T, 88T, 202T2 and 203T3), and from
them assemble contigs spanning the structural variant breakpoints. These contigs were realigned to the devil reference sequence
using BWA-MEM (Li, 2013). We selected those contigs that mapped to both scaffold locations predicted by BRASS. We analyzed
these alignments to determine the precise location of the breakpoint, to base pair resolution, and to categorize each as either
non-templated sequence insertions, microhomologies, or blunt-end breakpoints (Table S5). Of these selected contigs, those with
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were manually inspected using IGV to further validate the breakpoint junction sequences (Thorvaldsdo´ttir et al., 2013). As an addi-
tional check, the results obtained through our TIGRApipeline were also reproduced using the assembly based structural variant caller
SvABA (Wala et al., 2018).
Structural Variant Annotation
SV breakpoints were intersected with Ensembl gene predictions. SVs that were predicted within a gene footprint are annotated in
Table S5. Strand and frame information was used to predict the potential for SVs to create in-frame fusion genes (Tables S3 and S5).
Mutational Signature Analysis
SNV Spectra for Somatic Mutational Signatures
The set of tumor-unique SNVs for each tumor (see SNV and Indel Subsetting) were extracted, together with their immediate 5’ and 3’
contexts (96 mutation types). 86T and 88T tumor-unique variants were pooled, and 202T2 and 203T3 tumor-unique variants were
pooled, generating DFT1 and DFT2 somatic mutation sets, respectively. Triplet frequency normalization was done as follows. We
counted frequencies of the 32 pyrimidine-context nucleotide triplet combinations in the variant-calling accessible (see SNV and Indel
Calling) Devil7.1 reference. Each of the 96 observedmutation counts were then divided by its corresponding triplet frequency, prior to
rescaling the sum of mutational proportions to 100%.
Normalization of COSMIC Mutational Signatures
The thirty consensus mutational signatures derived from human cancers which are available in the COSMIC database (http://cancer.
sanger.ac.uk/cosmic/signatures; downloaded on 01/06/2017) and are relative to the human genome were normalized as follows: we
counted frequencies of the 32 pyrimidine-context nucleotide triplet combinations in the human reference genome GRCh37 (hg19).
Each of the 96 mutation proportions of each COSMIC signature were then divided by its corresponding triplet frequency, yielding a
species-agnostic mutational signature, prior to rescaling the sum of mutational proportions to 100%.
Fitting COSMIC Mutational Signatures DFT1 and DFT2 Spectra
We developed a Bayesian multinomial mixture model to refit known COSMIC mutational signatures to devil DFT1 and DFT2 somatic
spectra. The fitting is done using Markov Chain Monte Carlo sampling (MCMC), using the No-U-Turn sampler implemented in the
Stan programming language (Carpenter et al., 2017). In the model, the mutational signatures are interpreted as the probability pa-
rameters of independent multinomial distributions, and the observed mutation counts in the 96 mutational categories are treated
as draws from a mixture of these multinomials. The MCMC process samples mixture weights that specify the degree to which
each signature contributes to the observedmutations.We use a symmetrical, uniformDirichlet distribution as our prior on themixture
weights.
Model specification:W  Dirichlet (1) Prior on mixture weights
q = WS Multinomial mixture probabilities
M  Multinomial (q) LikelihoodM: 1396 vector of mutation counts by category;
1: 13K vector, each entry is 1;
W: 13K vector of mixture weights;
S: K396 matrix of mutational signatures;
K: number of mutational signatures;
q: 1396 vector of multinomial probabilities resulting from the mixture of mutational signatures, S, according to weights, W.
Given that human signatures 1 and 5 are almost universal in human cancer and normal tissues (Alexandrov et al., 2013, 2015a;
Blokzijl et al., 2016; Ju et al., 2017; Rahbari et al., 2016), we first fitted human signatures 1 and 5 to pooled DFT1 (6,812 variants)
and DFT2 (629 variants) variants.
Next, we assessed the improvement of fit when introducing the remaining 28 known human signatures. We assessed
cosine similarities between the DFT-unique spectra and double-fits of signatures 1, 5, as well as of any triple-fits of signatures
1, 5, N ˛ [2-4,6-30] (Table S2). In order to avoid overfitting, we set a minimum threshold of 0.02 cosine similarity increase between
1, 5 and any 1, 5, N signature combinations for significance, as previously described (Schulze et al., 2015). However, only signature
combinations 1, 5, 6 and 1, 5, 14 and 1, 5, 15 withstood this criterion in case of the fitting to the DFT1-unique spectrum (D0.0479 for
signature combination 1, 5, 6; D0.0492 for signature combination 1, 5, 14; D0.0669 for signature combination 1, 5, 15), whereas
no combinations surpassed D0.02 in the case of DFT2-unique variants (Table S2). As we did not detect the additional hallmarks
of signature 6 and 15 (large numbers of small (<3BP) indels atmono/polynucleotide repeats) or signature 14 (high numbers of somatic
mutations (>200 per megabase), see http://cancer.sanger.ac.uk/cosmic/signatures; last access on 05/10/2017), we believe that it is
unlikely that these signatures are present.Cancer Cell 33, 607–619.e1–e15, April 9, 2018 e14
Virus Screen and PAV Analysis
De Novo Genome Assembly
De novo assemblies were produced from four tumor genomes (86T and 88T (DFT1) and 202T2 and 203T3 (DFT2)) and two host ge-
nomes (202H1 and 203H).We used Fermi (Li, 2012) to perform base error corrections for raw reads, to remove erroneous sequencing
data and to generate a contig-wise assembly. We also ran Phusion2 (Mullikin and Ning, 2003) to obtain a second assembly with the
base error corrected short reads. SOAPdenovo (Li et al., 2010) was used to process the cleaned reads in a third assembly run, which
was improved using SSPACE (Boetzer et al., 2011). Next, Fermi/Phusion2 contigs were aligned to the SOAP scaffolds and assembly
gaps closed when a piece of Fermi/Phusion2 sequence bridged two neighboring SOAP scaffolds.
Presence/Absence Variation (PAV) Analysis
Presence/absence variations (PAVs) are the sequences that are present in one genome assembly, but which are undetectable in
another. We focused on identifying PAV contigs that were present one or more of the four tumor de novo assemblies, but which
were absent from the reference genome. We first built an alignment index for absence in the reference assembly Devil7.1 using
SMALT (https://sourceforge.net/projects/smalt/). In order to reduce CPU time, we shredded each tumor assembly into 1 kilobase
fragments while removing ‘N’ bases, prior to alignment against the indexed absence (Devil7.1) assembly. Last, we filtered out small
repetitive elements placed at ambiguous locations. We have integrated this software into a pipeline, scanPAV, which can be down-
loaded from https://github.com/wtsi-hpag/scanPAV/ (Giordano et al., 2018). This method produced a set of PAV candidate contigs
which had evidence for presence in one or more tumor genome assembly, but which appeared to be absent from the devil reference
genome. We further filtered these candidate tumor-specific PAV contigs by aligning sequence reads derived from the reference
genome (91H) to them. Contigs with 91H sequence coverage >10 X were removed.
To further filter candidate PAV contigs for absence across a panel of normal devil genomes, the set of candidate tumor-unique PAV
contigs were concatenated with Devil7.1 to create four Devil7.1+PAV assemblies, with each assembly carrying the set of PAVs
unique to one of the four tumors. Next, we extracted the set of sequence reads from tumors 86T, 88T, 202T2 and 203T3 and normal
devils 31H, 91H, 202H1 and 203H which previously did not map to Devil7.1, and aligned these to Devil7.1+PAV using BWA-MEM (Li,
2013). Wemeasured the read depth of each candidate PAV contig in each sample, and retained those contigs that had read depth of
at least 40% mean whole genome read depth in at least one tumor (thresholds were as follows, 86T – 34.4 X, 88T – 26.8 X, 202T2 –
26.8 X, 203T3 – 28.0 X), but that did not reach 20% whole genome read depth in any host (thus plausibly representing a single copy
integration event in tumors but not in normal genomes); the thresholds for hosts were as follows: 31H – 3.4 X, 91H – 13.0 X, 202H1 –
9.8 X, 203H – 9.0 X. After this filtering, a total of 139 candidate tumor-specific PAV contigs remained (Table S1). The tumor-specificity
of these contigs was assessed by aligning reads from the other three tumors to each individual tumor’s set of candidate PAVs. The
contigs were further evaluated by comparing against the NCBI ’nt’ sequence database with the default ’dc-megablast’ option in
BLAST+ 2.6.0 (Camacho et al., 2009). The top hit was annotated, including target species name, ID, BLAST identity, hit length, E-
value and bitscore (Table S1).
Y Chromosome Contig Identification
We used genome assemblies of a male host, 202H1, as well as DFT2 tumors 202T2 and 203T3 to identify Y chromosome contigs that
were present in these assemblies but whichwere absent in the female Tasmanian devil reference genomeDevil7.1. Contigs identified
in 202H1, 202T2 and 203T3 which were absent in the reference genome were screened using BLAT (Kent, 2002) for the presence
of a  825 BP dasyurid-specific intron located within the SRY gene (O’Neill et al., 1998). As an input query, we used the intronic
SRY sequence of the stripe-faced dunnart (Sminthopsis macroura). Identified sequences were used as seeds for alignments of
the neighboring exons with SRY cDNA sequences identified in rock wallabies (O’Neill et al., 1997).
Contigs devil-202H_4481 (202H1, length: 84,660 BP), devil-202T_3709 (202T2, length: 84,684 BP) and devil-203T_28242 (203T3,
length: 70,068 BP) were identified as Y chromosomal sequences harboring SRY.
Drug Screen IC50 Analysis
IC50 drug sensitivity values for different cell lines, as derived from our high-throughput screen, were used as an input for loge(IC50)
hierarchical clustering. This was performed by applying the default R hclust() function (method: ’complete’) on the Euclidian distance
matrix derived from each pairwise drug and cell line combination. Figure 5B shows data for 6 DFT cell lines clustered with 104 com-
pounds. IC50 data from human cell lineswas obtained from theGenomics of Drug Sensitivity in Cancer (GDSC) database (http://www.
cancerrxgene.org/, downloaded on 07/05/2017, Yang et al. (2013)).
DATA AND SOFTWARE AVAILABILITY
The accession number for genomic data reported in this paper is ENA: PRJEB21902. Additional materials such as IHC and
FISH images, mutational calls, Devil7.0 to Devil7.1 translations, genome assembly contigs and PAVs can be found on Mendeley
Data (https://doi.org/10.17632/znfphvhmbv.1). Code used in this study is made available on Github (https://github.com/
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